Spots Global Cancer Trial Database for Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

Official Title: Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

Study ID: NCT03520153

Conditions

McCune-Albright Syndrome

Fibrous Dysplasia

Intraductal Papillary Mucinous Neoplasm

Diabetes Mellitus

Interventions

Hyperinsulinemic Euglycemic Clamp and 2H20

Hyperglycemic Clamp

Oral Glucose Tolerance Test

Study Description

Brief Summary: The investigators' objective is to understand the pathogenesis of diabetes mellitus in Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of insulin resistance versus impaired insulin secretion, 2) investigating presence of excess glucagon signaling by measuring gluconeogenesis and glycogenolysis, and 3) investigating a potential interaction between diabetes and intraductal papillary mucinous neoplasms (IPMNs).

Detailed Description: Specific project aims include: Aim 1: Determine insulin secretion and sensitivity in subjects with MAS-associated diabetes. Aim 2: Measure gluconeogenesis and glycogenolysis in MAS-associated diabetes to investigate a potential role for excess glucagon signaling. Aim 3: Determine if IPMN development is associated with impairment of insulin secretion prior to development of overt diabetes. The authors expect that this study will: 1. Establish the etiology of diabetes in FD/MAS 2. Increase understanding of the role of IPMNs in pathogenesis of diabetes 3. Provide critical insights into the pathogenesis of diabetes in FD/MAS